The problem is not the 800m placement, it is the unknown sp. He should be out there talking up the expected data and the possible return for investors like ALA did with its useless iNKT tech. CHM already got fantastic clinical data and like all the other times he talks those down as crap. That's the problem, the Ts & Cs.
He is the only ASX chair doing it and the sp of RAD, IMU and CHM have suffered big time whilst others have recovered.
CHM Price at posting:
2.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)